title: Pemphigoid gestationis: a retrospective study in southwest Iran.
abstract: Pemphigoid gestationis (PG) is a rare autoimmune bullous dermatosis of pregnancy usually presents in the second or third trimester. It is characterized by pruritic, urticarial plaques with the development of tense vesicles and bullae within the lesions. Pathogenesis of PG is not fully established, however, most patients develop circulating autoantibodies targeting the bullous pemphigoid (BP) 180 antigen. The aim of this work is to draw a profile of the epidemiology, clinical aspects, treatment and evolution of the disease by studying hospital series. We retrospectively investigated the 13 patients who were diagnosed with PG based on hospital data at the Referral Center of Southwest Iran located in Ahvaz city between March 2002 and March 2011. The age of onset was 21 to 40 years (mean age: 27.5 years). The onset of the disease occurred in the second trimester of pregnancy in 6 patients and in the third trimester of pregnancy in 4 patients. One patient had a flare up of disease during the first trimester and two out of cases in puerperium period. In all cases, pruritus was the first symptom, followed by an erythematous vesiculobullous eruption.  The diagnosis of PG was confirmed by skin biopsy. Ten out of the patients treated with oral corticosteroids (0.5-1 mg/kg/day), one of the patients underwent oral corticosteroids plus topical glucocorticoid and the last patient treated with topical glucocorticoid. PG remains a rare dermatosis of pregnancy. Our series had two particularities compared to other studies: high frequency in primigravida and the frequent involvement of the face. Additionally our study demonstrated that improvement could occur faster and provide acceptable management if the treatment of the patients would be implemented sooner.
authors.affiliation: Department of Dermatology, Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors.forename: Sima
authors.initials: S
authors.lastname: Rassai
authors.forename: Nader
authors.initials: N
authors.lastname: Pazyar
authors.forename: Seyed Milad
authors.initials: SM
authors.lastname: Alavi
authors.forename: Afshin
authors.initials: A
authors.lastname: Kazerouni
authors.forename: Amir
authors.initials: A
authors.lastname: Feily
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007492:Iran / Q000453:epidemiology; D006559:Pemphigoid Gestationis / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications; D011263:Pregnancy Trimester, Third; D012189:Retrospective Studies; D012867:Skin / Q000473:pathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D005938:Glucocorticoids